Medtronic and Lilly partner to improve delivery of diabetes education

5 June 2009

Medtronic, Inc. (NYSE:MDT) and Eli Lilly and Company (NYSE:LLY) have entered a strategic marketing collaboration to support each other's commitment to help people with diabetes manage their blood sugar using insulin therapy.

Working collaboratively with healthcare professionals, Medtronic and Lilly marketing and sales operations in the United States will work to improve the delivery of diabetes education for insulin-taking patients and their caregivers.

This includes the development of new educational resources and classes around the initiation and intensive management of insulin, insulin pump therapy and continuous glucose monitoring (CGM).

The alliance combines the insulin expertise of Lilly, a worldwide leader in diabetes treatment, research and education, with the advanced diabetes technologies of Medtronic, the world’s largest manufacturer of insulin pumps and CGM, and maker of an integrated diabetes management system that combines the power of insulin pump therapy with CGM.

“Medtronic and Lilly are joining together to help improve patient access to high-quality diabetes education,” said Chris O’Connell, president of the Diabetes business unit and senior vice president at Medtronic.

“Because diabetes management is complicated, it is crucial that physicians and patients have the best access to information and educational resources. This collaboration will generate greater awareness and enable more people to benefit from the latest educational tools regarding insulin pump therapy and continuous glucose monitoring.”

“People with diabetes have numerous treatment options and devices to help manage blood sugar, but physicians and patients need resources and solutions to integrate these improvements into real-world therapy,” said Matt Beebe, Diabetes brand leader, Lilly USA, LLC.

“With this alliance, Lilly and Medtronic hope to create integrated solutions to address challenges for people taking insulin who need optimal glycemic control. By joining forces, we will help make insulin therapy more achievable by offering new educational materials and resources that help make insulin pump therapy fit into patients’ lives.”

Bookmark this page

To top